Kids and Antidepressants: A Growing Problem
No. 3 of the Top 10 Stories of 2004: The FDA warned of a drug-suicide link this year. Are we rushing to medicate our kids or rushing to judgment about drugs that may truly help some of them?
On Feb. 2, 2004, Mark Miller of Overland, Kan., spoke at a public forum in the nation's capital, uttering words that no parent should ever have to speak:
"This is important for you to know," he told an FDA advisory committee. "Matt hung himself from a bedroom closet hook, barely higher than he was tall. To commit this unthinkable act, something he had never attempted before, never threatened to any family member, never talked about, he was actually able to pull his legs up off the floor and hold himself that way until he lost consciousness and forced himself to leave us."
Matt Miller was 13 when he took his own life in the summer of 1997.
"He died after a psychiatrist we did not know gave him three sample bottles of a pill we had never heard of, for a perceived illness that his doctor could only guess at," his father testified. "We were advised with great authority that Matt was suffering from a chemical imbalance that could be helped by a new, wonderful medication called Zoloft. It was safe, effective, only two minor side effects were cautioned with us: insomnia, indigestion."
In March 2004, the FDA issued a public health advisory about the potential for increased suicidal thoughts and actions among people who take antidepressants, particularly drugs in the relatively new subclass of agents known as "selective serotonin reuptake inhibitors," or "SSRIs" for short. They work by allowing the body to make more effective use of the brain chemical serotonin, which is a messenger involved in the regulation of mood, emotion, appetite, and sleep. Widely prescribed brand-name drugs in this class include Celexa, Lexapro, Paxil, Prozac, and Zoloft.
In October 2004, the FDA, following recommendations of the advisory committee, ordered makers of all antidepressant medications - not just SSRIs -- to include a "black box" warning and cautionary statements on drug labeling that will "alert health care providers to an increased risk of suicidality (suicidal thinking and behavior) in children and adolescents being treated with these agents."
Britain's Medicines and Healthcare Products Regulatory Agency issued similar warnings in early December, urging doctors to consider alternative therapies and, when prescribing an antidepressant, to prescribe only low doses and monitor patients carefully.
In the pharmaceutical industry, a black box on a product's label is a stark reminder that for every benefit, every "miracle drug," there is a risk. In the case of widely prescribed and heavily marketed antidepressants, the benefits of relief from symptoms of major clinical depression must be weighed against the relatively infrequent but potentially devastating risks of worsening of depression or suicide.
There is little dispute that antidepressants have helped millions of adults with major depression and other debilitating mental disorders. There is also, however, growing concern among doctors, child safety advocates, and parents that these heavily marketed mind-altering agents are being used too freely and with too little research into their effects in children and adolescents.
In a statement praising the FDA's action in March, Martha Hellander, JD, executive director of the Child and Adolescent Bipolar Foundation, called it "a wake-up call that these powerful and lifesaving drugs used to heal depression may trigger a paradoxical response in some children that parents need to know about."